SavedAdd your journal

Journals / Türk Onkoloji Dergisi / 2019 / Cilt: 34 - Sayı: 2

An incidentally Diagnosed Hepatocellular Carcinoma That Exhibited Unusual Metastasis

Tuba TASLAMACIOĞLU DUMAN
Selma ERDOĞAN DÜZCÜ
Meryem DEMİR
Buket Büşra BAŞAR
Ümmügül ÜYETÜRK
Pages
114–118
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We aimed topresent with literature the case of HCC that was diagnosed incidentally and had rare metastasis of softtissue and CNS and long-term overall survival.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hepatocellular carcinoma (HCC) is the most common primary liver cancer.
📊
Key Findings & Data:The incidence of CNS metastasis ranges from 0.6% to1.7%.
💡
Conclusion & Impact:We aimed topresent with literature the case of HCC that was diagnosed incidentally and had rare metastasis of softtissue and CNS and long-term overall survival.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver cancer. It can be diagnosed at alate stage due to the lack of early symptom onset and its non-pathognomonic symptoms. Metastaticregions often include the lung, lymph nodes, bones, and adrenal glands. Soft tissue and central nervoussystem (CNS) metastases are extremely rare. The incidence of CNS metastasis ranges from 0.6% to1.7%. Curative treatment is liver transplantation or resection in early stages. In advanced stages, localtherapies include transarterial chemoembolization and radioembolization. Systemic treatments, such assorafenib, regorafenib, ramucirumab, and nivolumab, are applied in the metastatic stage. We aimed topresent with literature the case of HCC that was diagnosed incidentally and had rare metastasis of softtissue and CNS and long-term overall survival.

🔖

Cite This Article

DUMAN, T. T., DÜZCÜ, S. E., DEMİR, M., BAŞAR, B. B., ÜYETÜRK, Ü. (2022). An incidentally Diagnosed Hepatocellular Carcinoma That Exhibited Unusual Metastasis. Türk Onkoloji Dergisi, Cilt: 34 - Sayı: 2, 114–118. https://ajindex.com/articles/639208

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sourcesand methods. Int J Cancer 2019;144(8):1941– 53
  2. Chung JW, Jang ES, Kim J, Jeong SH, Kim N, Lee DH, et al. Development of a nomogram for screening of hepatitis B virus-associated hepatocellular carcinoma. Oncotarget 2017;8(63):106499–510
  3. Makarova-Rusher OV, Altekruse SF, McNeel TS, Ulahannan S, Duffy AG, Graubard BI, et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer 2016;122(11):1757–65
  4. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S35–50
  5. Motola-Kuba D, Zamora-Valdés D, Uribe M, Méndez-Sánchez N. Hepatocellular carcinoma. An overview. Ann Hepatol 2006;5(1):16–24
  6. Sartori Balbinot R, Facco Muscope AL, Dal Castel M, Sartori Balbinot S, Angelo Balbinot R, Soldera J. Intraparenchymal Hemorrhage due to Brain Metastasis of Hepatocellular Carcinoma. Case Rep Gastroenterol 2017;11(3):516–25
  7. Rinninella E, Cerrito L, Spinelli I, Cintoni M, Mele MC, Pompili M, et al. Chemotherapy for Hepatocellular Carcinoma: Current Evidence and FuturePerspectives. J Clin Transl Hepatol 2017;5(3):235–48
  8. Daher S, Massarwa M, Benson AA, Khoury T. Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review. J Clin Transl Hepatol 2018;6(1):69–78
  9. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378–90. 10.Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10(1):25–34. 11.Casadei Gardini A, Foca F, Scartozzi M, Silvestris N, Tamburini E, Faloppi L, et al. Metronomic capecitabine versus best supportive care as secondline treatment in hepatocellular carcinoma: a retrospective study. Sci Rep 2017;7:42499. 12.Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al.; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389(10064):56–66.